Palmitoylated elastin-derived hexapeptide (Pal-VGVAPG) proposed to inhibit NMJ acetylcholine release. Weakest evidence position in Cluster G — no published clinical trials, no PubMed-indexed mechanistic studies for NMJ activity, molecular target uncharacterized in public literature.

📖 Read the full Palmitoyl Hexapeptide-12 research overview →

Evidence Tier: Tier 4 — Preclinical Only · Peptidings Verdict: Thin Ice